FPFrancesco Pisani

Francesco Pisani

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Francesco Pisani has a total of 134 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Scalp high‐frequency oscillations differentiate neonates with hypoxic–ischemic encephalopathy with and without electroencephalographically confirmed seizures

    by Panagiota Karatza, Dorottya Cserpan, Antonio Giulio Gennari, Anina Grubenmann, Santo Pietro Lo Biundo, Francesco Pisani, Johannes Sarnthein, Georgia Ramantani

    Objective: Hypoxic–ischemic encephalopathy (HIE) is a leading cause of neonatal seizures, but seizure detection is challenging when continuous electroencephalography (EEG) is unavailable and neonates undergo only a single routine EEG. Biomarkers derived from routine EEG may aid identification of neonates with seizures. We investigated whether scalp high‐frequency oscillation (HFO) rates derived from the first eligible routine EEG (1) differentiate neonates with HIE with and without seizures; and (2) contribute to seizure classification alongside established clinical, neurophysiological, and imaging biomarkers. Methods: We retrospectively analyzed routine scalp EEG recordings from 33 term neonates with HIE (17 with seizures, 16 without), obtained at a mean postnatal age of 4 ± 3 days. The mean analyzed EEG duration was 38 ± 14 min in neonates with seizures and 36 ± 20 min in those without. HFO rates in sleep segments were quantified using a validated automated detector. Results: Scalp HFO rates were significantly higher in neonates with seizures than in those without (.12 ± .11 vs. .03 ± .02 HFOs/min/channel, adjusted p = .02). An HFO rate threshold of .07 HFOs/min/channel optimally discriminated neonates who had seizures from those who did not (area under the curve [AUC] = .81). HFO rates did not differ significantly according to HIE severity, therapeutic hypothermia, antiseizure medication response, EEG background activity, or magnetic resonance imaging (MRI) abnormalities. Multivariable models incorporating HFO rate, EEG background activity, and MRI findings showed discrimination (AUC = .92, 95% confidence interval [CI] = .69–1.00 for logistic regression; AUC = 1.00, 95% CI = .75–1.00 for random forest), with HFO rate as the strongest contributor to seizure classification. Significance: These findings support scalp HFO rate as a potential electrophysiological biomarker of seizure occurrence in neonatal HIE , complementary to EEG background assessment and MRI findings. Prospective studies are needed to determine whether HFOs can predict subsequent seizures.

  • Open Access

    Nuclear respiratory factor 1 promotes cell survival in multiple myeloma under proteasome inhibition therapy

    by Tiziana Bruno, Maria Chiara Cappelletto, Clelia Cortile, Stefano Di Giovenale, Bruno Amadio, Francesca De Nicola, Italia Falcone, Stefano Giuliani, Belinda Palermo, Valeria Catena, et al.

    Multiple myeloma (MM) continues to be an incurable malignancy, even with recent therapeutic advancements. Although epigenetic dysregulation at cis-regulatory elements is known to drive disease progression, the complete molecular mechanisms underlying these alterations are poorly understood. Using Assay for Transposase-Accessible Chromatin with high-throughput sequencing analysis combined with the computational footprinting of CD138+ cells from 55 patients with MM, we depicted the dynamic changes in chromatin accessibility during disease progression and identified nuclear respiratory factor 1 (NRF1) as a master regulator of vital MM survival pathways. We demonstrated that NRF1 maintains proteasome homeostasis by orchestrating the ubiquitination pathway, which is essential for MM cell survival. We discovered a novel enhancer element that physically interacts with the NRF1 promoter, sustaining its expression. Targeting this enhancer RNA reduced NRF1 levels and increased tumor cell sensitivity to bortezomib (BTZ), suggesting therapeutic potential. In xenograft models, we showed that antisense oligonucleotides targeting the NRF1 enhancer, either alone or combined with BTZ, significantly decreased tumor burden and improved survival. Our findings reveal a previously unknown NRF1-dependent mechanism regulating MM cell survival and present a promising therapeutic approach through the manipulation of its regulatory network.


  • Open Access

    Scalp high‐frequency activity differentiates neonates with seizures from healthy neonates and indicates postneonatal epilepsy risk

    by Panagiota Karatza, Dorottya Cserpan, Santo Pietro Lo Biundo, Andrea Rüegger, Francesco Pisani, Johannes Sarnthein, Georgia Ramantani

    Objective: This study investigated whether scalp high‐frequency activity (HFA) rates in neonates with seizures predict postneonatal epilepsy (PNE). It also assessed whether HFA rates differentiate neonates with seizures from healthy neonates and whether they vary by seizure etiology, therapeutic hypothermia, and electroencephalographic (EEG) background activity. Methods: We included 47 neonates with EEG‐confirmed seizures (nine with neonatal mortality, three lost to follow‐up, 35 with 1‐year follow‐up), and eight healthy neonates. Scalp HFA rates during sleep were determined using an automated detector. Results: Neonatal seizure etiologies included hypoxic–ischemic encephalopathy (HIE, n = 16), structural vascular lesions (SVL, n = 14), and neonatal onset genetic epilepsies ( n = 14). Scalp HFA rates were significantly higher in neonates with seizures (.16 ± .15 HFA/min/channel [ch]) than in healthy neonates (.03 ± .02 HFA/min/ch), with a threshold of .06 HFA/min/ch best differentiating these groups. Among neonates with seizures, those with genetic etiologies had significantly higher HFA rates (.24 ± .19 HFA/min/ch) than those with SVL (.07 ± .05 HFA/min/ch). HFA rates were not associated with EEG background activity and were unaffected by therapeutic hypothermia in neonates with HIE. Of the 35 surviving neonates with seizures, 11 developed PNE, whereas 16 had normal development at follow‐up. Neonates who developed PNE had significantly higher HFA rates (.27 ± .18 HFA/min/ch) than those with normal development (.11 ± .09 HFA/min/ch), with a threshold of .12 HFA/min/ch best differentiating these groups. Significance: Scalp HFA differentiates neonates with seizures from healthy neonates and may help identify those at higher risk for PNE. These findings support the potential use of scalp HFA as a potential biomarker for seizure monitoring and epilepsy risk stratification in neonates.


  • Open Access

    IELSG30 phase 2 trial: intravenous and intrathecal CNS prophylaxis in primary testicular diffuse large B-cell lymphoma

    by Annarita Conconi, Annalisa Chiappella, Andrés J. M. Ferreri, Anastasios Stathis, Barbara Botto, Marianna Sassone, Gianluca Gaidano, Monica Balzarotti, Francesco Merli, Alessandra Tucci, et al.

    Primary testicular diffuse large B-cell lymphoma (PTL) is characterized by high risk of contralateral testis and central nervous system (CNS) relapse. Chemoimmunotherapy with intrathecal (IT) CNS prophylaxis and contralateral testis irradiation eliminates contralateral recurrences and reduces CNS relapses. The IELSG30 phase 2 study investigated feasibility and activity of an intensified IT and IV CNS prophylaxis. Patients with stage I/II PTL who had not received treatment received 2 cycles of IV high-dose methotrexate (MTX) (1.5 g/m2) after 6 cycles of the R-CHOP regimen (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone, every 21 days). IT liposomal cytarabine was administered on day 0 of cycles 2 to 5 of 21-day R-CHOP regimen. Contralateral testis radiotherapy (25-30 Gy) was recommended. Fifty-four patients (median age: 66 years) with stage I (n = 32) or II (n = 22) disease were treated with R-CHOP, 53 received at least 3 doses of IT cytarabine, 48 received at least 1 dose of IV MTX, and 50 received prophylactic radiotherapy. No unexpected toxicity occurred. At a median follow-up of 6 years, there was no CNS relapse; 7 patients progressed, and 8 died, with 5-year progression-free and overall survival rates of 91% (95% confidence interval [CI], 79-96) and 92% (95% CI, 81-97), respectively. Extranodal recurrence was documented in 6 patients (in 2 without nodal involvement). In 4 cases, the relapse occurred >6 years after treatment. Causes of death were lymphoma (n = 4), second primary malignancy (n = 1), cerebral vasculopathy (n = 1), unknown (n = 2). Intensive prophylaxis was feasible and effective in preventing CNS relapses. Late relapses, mainly at extranodal sites, represented the most relevant pattern of failure. This trial was registered at www.clinicaltrials.gov as #NCT00945724.


  • Top Cited Papers

    High Levels of Circulating Tumor Plasma Cells as a Key Hallmark of Aggressive Disease in Transplant-Eligible Patients With Newly Diagnosed Multiple Myeloma

    by Luca Bertamini, Stefania Oliva, Delia Rota-Scalabrini, Laura Paris, Sonia Morè, Paolo Corradini, Antonio Ledda, Massimo Gentile, Giovanni De Sabbata, Giuseppe Pietrantuono, et al.

    PURPOSE: High levels of circulating tumor plasma cells (CTC-high) in patients with multiple myeloma are a marker of aggressive disease. We aimed to confirm the prognostic impact and identify a possible cutoff value of CTC-high for the prediction of progression-free survival (PFS) and overall survival (OS), in the context of concomitant risk features and minimal residual disease (MRD) achievement.METHODS: CTC were analyzed at diagnosis with two-tube single-platform flow cytometry (sensitivity 4 × 10–5) in patients enrolled in the multicenter randomized FORTE clinical trial (ClinicalTrials.gov identifier: NCT02203643 ). MRD was assessed by second-generation multiparameter flow cytometry (sensitivity 10–5). We tested different cutoff values in series of multivariate (MV) Cox proportional hazards regression analyses on PFS outcome and selected the value that maximized the Harrell's C-statistic. We analyzed the impact of CTC on PFS and OS in a MV analysis including baseline features and MRD negativity.RESULTS: CTC analysis was performed in 401 patients; the median follow-up was 50 months (interquartile range, 45-54 months). There was a modest correlation between the percentage of CTC and bone marrow plasma cells ( r = 0.38). We identified an optimal CTC cutoff of 0.07% (approximately 5 cells/µL, C-index 0.64). In MV analysis, CTC-high versus CTC-low patients had significantly shorter PFS (hazard ratio, 2.61; 95% CI, 1.49 to 2.97, P < .001; 4-year PFS 38% v 69%) and OS (hazard ratio, 2.61; 95% CI, 1.49 to 4.56; P < .001; 4-year OS 68% v 92%). The CTC levels, but not the bone marrow plasma cell levels, affected the outcome. The only factor that reduced the negative impact of CTC-high was the achievement of MRD negativity (interaction P = .039).CONCLUSION: In multiple myeloma, increasing levels of CTC above an optimal cutoff represent an easy-to-assess, robust, and independent high-risk factor. The achievement of MRD negativity is the most important factor that modulates their negative prognostic impact.


  • Allogeneic hematopoietic stem cell transplantation in Primary Cutaneous T Cell Lymphoma

    by Laura Cudillo, William Arcese For The Rome Transplant Network, Raffaella Cerretti, Alessandra Picardi, Benedetta Mariotti, Gottardo De Angelis, Maria Cantonetti, Massimiliano Postorino, Eleonora Ceresoli, Giovanna De Santis, et al.

    In our retrospective study, 16 patients affected by advanced cutaneous T cell lymphoma (CTCL) underwent allogeneic hematopoietic stem cell transplantation (HSCT). Two patients (12.5%) were in complete remission (CR), nine (56.3%) in partial remission (PR), and five (31.2%) with active disease. The patients were transplanted from an HLA-identical (n = 7) from a mismatched (n = 1) or haploidentical (n = 1) sibling, from matched unrelated donor (n = 5), or from a single cord blood unit (n = 2). Conditioning regimen was standard myeloablative in 6 patients and at reduced intensity in 10. Seven patients died from non relapse mortality (NRM) and four patients relapsed or progressed, three of them achieved a second CR after donor lymphocyte infusion (DLI) or chemotherapy plus DLI. To date, with a median follow-up of 76 months (range 6–130), nine patients are alive, eight in CR, and one with active disease. Overall survival (OS) and disease-free survival (DFS) at 1 and 10 years are 61% (95% CI 40–91%) and 54% (95% CI 33–86%), 40% (95% CI 22–74%), and 34% (95% CI 16–68%), respectively. The time from diagnosis to transplant seems to influence negatively both OS (log-rank p < 0.04) and DFS (log-rank p < 0.05). Our results confirm on a long follow-up that CTCL appears particularly susceptible to the graft versus lymphoma (GVL) effect, so that allogeneic HSCT represents a possibility of cure for advanced CTCL. The timing of HSCT in the clinical course of disease remains an open issue.


  • Neonatal seizure automatism and human inborn pattern of quadrupedal locomotion

    by E. Pavlidis, G. Cantalupo, L. Cattani, C.A. Tassinari, F. Pisani


  • Spatio-temporal video processing for respiratory rate estimation

    by Davide Alinovi, Luca Cattani, Gianluigi Ferrari, Francesco Pisani, Riccardo Raheli

    In this paper, we present a wire-free, low-cost video processing-based technique for respiratory rate (RR) estimation. The proposed method blends together two recently presented techniques, with the purpose of emphasizing small movements, such as respiratory movements possibly present in a video stream, in order to detect them. Initially, the system performs a spatial decomposition of the video frames in a pyramidal representation, in which each layer contains different spatial details. The levels are then pixel-wise temporally filtered with an infinite impulse response (IIR) filter, purposely designed to extract components having a periodicity compatible with the respiratory rate. Afterwards a single motion signal is extracted from each level. Finally, the extracted signals are jointly analyzed according to the maximum likelihood (ML) criterion in order to estimate the respiratory rate. The parameters extracted by our algorithm show a good agreement with those indicated by a gold-standard polysomnographic system. Therefore, our results, although preliminary, are encouraging and show that the respiratory rate can be reliably measured and monitored by a low-cost, wire-free, video processing-based system.


  • Open Access

    Prognostic factors associated with progression of smoldering multiple myeloma to symptomatic form

    by Angela Rago, Sara Grammatico, Tommaso Za, Anna Levi, Sergio Mecarocci, Agostina Siniscalchi, Luca De Rosa, Stefano Felici, Velia Bongarzoni, Anna Lina Piccioni, et al.

    BACKGROUND: Smoldering multiple myeloma (SMM) presents a high risk of progression to symptomatic MM (sy-MM). Herein, we analyzed some predictors of development of sy-MM. In 144 patients with SMM, we also compared the risk of progression predicted by bone marrow plasma cell (BMPC) involvement on the bone marrow biopsy (BMB) versus bone marrow aspirates (BMA). METHODS: From January 1980 to July 2010, 397 patients with SMM observed in 12 centers of the Multiple Myeloma GIMEMA (Gruppo Italiano Malattie EMatologiche dell'Adulto) Latium Working Group have been analyzed. At progression to sy-MM, the severity of clinical presentation was graded according to the need of intensive supportive care. RESULTS: After a median follow-up of 135 months, the cumulative incidence of progression rates to sy-MM were 45%, 55%, and 75% at 10, 15, and 20 years, respectively. Hemoglobin ≤12.5 g/dL, monoclonal component ≥2.5 g/dL, and BMPC ≥60% were the only parameters negatively affecting the cumulative incidence of progression. In particular, 10 of 397 (2.5%) patients with BMPC ≥60% had a 5.6-fold increased risk of fast progression (within 2 years), which occurred with severe clinical manifestations in 62% of cases. BMB was more sensitive for the detection of BMPC involvement, even though BMA was a more reliable indicator of a rapid progression to sy-MM. CONCLUSIONS: The highest risk of rapid evolution to sy-MM and the severity of clinical manifestation at the progression suggest that SMM patients with a BMPC ≥60% should be treated soon after diagnosis. Moreover, BMPC is a more reliable index for progression to sy-MM if assessed by BMA. Cancer 2012. © 2012 American Cancer Society.


  • Open Access

    Evolution of bisphosphonate-related osteonecrosis of the jaw in patients with multiple myeloma and Waldenstrom's macroglobulinemia: a retrospective multicentric study

    by A Andriani, M T Petrucci, T Caravita, M Montanaro, N Villivà, A Levi, A Siniscalchi, V Bongarzoni, F Pisani, M De Muro, et al.

    Bisphosphonates (BPs) are used intravenously to treat cancer-related conditions for the prevention of pathological fractures. Osteonecrosis of the jaw (BRONJ) is a rare complication reported in 4–15% of patients. We studied, retrospectively, 55 patients with multiple myeloma or Waldenstrom's macroglobulinemia followed up from different haematological departments who developed BRONJ. All patients were treated with BPs for bone lesions and/or fractures. The most common trigger for BRONJ was dental alveolar surgery. After a median observation of 26 months, no death caused by BRONJ complication was reported. In all, 51 patients were treated with antibiotic therapy, and in 6 patients, this was performed in association with surgical debridement of necrotic bone, in 16 with hyperbaric O2 therapy/ozonotherapy and curettage and in 12 with sequestrectomy and O2/hyperbaric therapy. Complete response was observed in 20 cases, partial response in 21, unchanged in 9 and worsening in 3. The association of surgical treatment with antibiotic therapy seems to be more effective in eradicating the necrotic bone than antibiotic treatment alone. O2 hyperbaric/ozonotherapy is a very effective treatment. The cumulative dosage of BPs is important for the evolution of BRONJ. Because the most common trigger for BRONJ was dental extractions, all patients, before BP treatment, must achieve an optimal periodontal health.